CogState CEO Brad O’Connor speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. CogState is focused on developing neuroscience technology that optimises brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. CogState’s technologies provide rapid, reliable and highly sensitive computerised cognitive tests and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.
#CogState #brainhealth #asx #proactiveaustralia
source
